SOUTH SAN FRANCISCO, Calif., June 29, 2015 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced that it has been named to the Bay Area News Group's prestigious Top Workplaces list for the second year in a row. The news group selects Top Workplace winners based solely on an annual survey of Bay Area-company employees.
"We are humbled and honored that the degree to which Veracyte values our employees and their individual contributions is reflected in their experiences with the company," said Bonnie H. Anderson, president and chief executive officer of Veracyte. "Receiving this award for a second year validates our emphasis on hiring and retaining creative, collaborative professionals who contribute to our goal of dramatically improving patient care."
The Bay Area News Group, which owns the San Jose Mercury News, Oakland Tribune, Contra Costa Times and other media properties, ranked Veracyte as one of the top small businesses to work for in the Bay Area, based on 2015 survey results measuring employee engagement, organizational health, satisfaction and company culture. The employee survey is conducted by WorkplaceDynamics, LLP, a leading research firm on organizational health and employee engagement.
The Bay Area News Group published the complete list of Top Workplaces on Sunday, June 28. The list of winners is available on the San Jose Mercury News website.
Veracyte's corporate and industry leadership have been recognized consistently over the past several years. Among other awards, Genetic Engineering and Biotechnology News recently selected Veracyte for its "Top 20 Up-and-Coming Molecular Diagnostics Companies" list and FierceMedicalDevices included the company among its annual "Fierce 15" for 2013. Fast Company recently named Ms. Anderson to its list of "100 Most Creative People in Business 2015" and the San Francisco Business Times previously selected her as one of the "Bay Area's Most Admired CEOs."
Veracyte (NASDAQ: VCYT) is pioneering the field of molecular cytology, focusing on genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's first commercial solution, the Afirma® Thyroid FNA Analysis, centers on the proprietary Afirma Gene Expression Classifier (GEC) to resolve ambiguity in diagnosis and is becoming a new standard of care in thyroid nodule assessment. The Afirma test is recommended in leading practice guidelines and is covered for approximately 150 million lives in the United States, including through Medicare and many commercial insurance plans. Veracyte intends to expand its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In April 2015, the company launched the Percepta™ Bronchial Genomic Classifier, a test to resolve preoperative ambiguity in lung nodules that are suspicious for cancer. Veracyte is also developing a second product in pulmonology, targeting interstitial lung diseases, including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.